Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis

This study aimed to investigate the pharmacodynamic effects of indobufen and low-dose aspirin in patients with coronary atherosclerosis.

In the first phase, 218 patients with coronary atherosclerosis were randomly assigned to receive aspirin 100 mg once daily (standard dose); 100 mg once every 2 days; 100 mg once every 3 days; 50 mg twice daily; 75 mg once daily; 50 mg once daily; or indobufen 100 mg twice daily for 1 month. In the second phase, 20 healthy subjects were treated with indobufen 100 mg twice daily for 1 week followed after a 2-week washout by aspirin 100 mg once daily for 1 week. The primary outcome was arachidonic acid-induced platelet aggregation (PL_AA), and the secondary outcomes included plasma thromboxane B₂ (TXB₂) and urinary 11-dehydro-TXB₂ (11-dh-TXB₂) levels at the end of each treatment.  RESULTS: In the first phase, compared with aspirin 100 mg once daily: all aspirin groups had similar suppression of PL_AA whereas indobufen group had significantly less suppressed PL_AA. Aspirin given every second or third day, and indobufen produced less suppression of plasma TXB₂. All treatment regimens produced similar inhibition of 11-dh-TXB₂. In the second phase, compared with aspirin, indobufen produced less suppression of plasma TXB₂ at 8 h and 12 h after the last dose.

Aspirin 50 mg twice daily, 75 mg once daily, and aspirin 50 mg once daily produce antiplatelet effects that are similar to aspirin 100 mg once daily. Aspirin given less often than once daily and indobufen 100 mg twice daily do not suppress platelets as effectively as aspirin 100 mg once daily.